Type 2 Diabetes Pharmacotherapy Decision Support
Based on ADA Standards of Care in Diabetes — 2026, Section 9
Demographics
Age (years)
Sex
Female
Male
Other / Unspecified
Pregnant
Physical Examination
Weight (kg)
Height (cm)
Systolic BP (mmHg)
Diastolic BP (mmHg)
Key Medical History
Established ASCVD
MI, stroke, revascularization, TIA, unstable angina, amputation, symptomatic CAD
Indicators of high CV risk
typically ≥55 yrs + ≥2 of: obesity, HTN, smoking, dyslipidemia, albuminuria
Heart failure
HF type
— not applicable —
HFrEF (EF ≤ 40%)
HFpEF (EF > 40%)
Currently symptomatic
MASLD (metabolic dysfunction–associated steatotic liver disease)
Biopsy-proven MASH or high risk of liver fibrosis
Prior pancreatitis
Personal/family history of medullary thyroid CA or MEN 2
Severe / proliferative diabetic retinopathy
Prior DKA
Currently symptomatic hyperglycemia
polyuria, polydipsia, weight loss
Laboratory Data
HbA1c (%)
Individualized A1C target (%)
Fasting / random glucose (mg/dL)
eGFR (mL/min/1.73 m²)
UACR (mg/g)
ALT (U/L)
AST (U/L)
On maximally tolerated ACEi/ARB
Current Glucose-lowering Medications
Metformin
SGLT2 inhibitor
GLP-1 RA
Dual GIP / GLP-1 RA (tirzepatide)
DPP-4 inhibitor
Sulfonylurea
TZD (pioglitazone)
Insulin
Treatment Goals & Context
Weight reduction is a stated priority
Minimize hypoglycemia risk (e.g., frail, older, lives alone)
Cost / access is a major constraint
Generate Recommendations
Reset